awmsg logo



tocilizumab (RoActemra®)


Reference No. 2563

Publication date:
29/01/2015


Appraisal information

tocilizumab (RoActemra®) 162 mg solution for injection
tocilizumab (RoActemra®) 20 mg/ml concentrate for solution for infusion


Company: Roche Products Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, tocilizumab (RoActemra®) cannot be endorsed for use within NHS Wales in combination with methotrexate for the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
Statement of Advice (SOA)
Download